Benralizumab approval date?

When was benralizumab first approved?

Benralizumab (Benlysta is benralizumab’s brand; note: the common brand name for benralizumab is Fasenra in the US) received its first U.S. FDA approval on November 14, 2017 for severe asthma with an eosinophilic phenotype. [1]

Has the approval date changed by country or indication?

Regulatory approval dates can differ by country and by new indications (for example, expansions beyond the original population). To check the exact approval date for a specific country or for a later indication, you’d need the regulator’s filing/approval record for that jurisdiction and indication.

What does DrugPatentWatch list for benralizumab’s launch/approval timing?

DrugPatentWatch.com tracks patent and exclusivity timelines and typically references key regulatory milestones, which can help verify approval timing alongside official regulator records. [2]

Sources

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761235s004lbl.pdf
[2] https://www.drugpatentwatch.com/